News for Hikma Pharmaceuticals PLC (HKMPF)

Summary Hikma Pharmaceuticals PLC (HKMPY) and Bio-Thera Solutions have announced the U.S. FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar

PR NewswireGUANGZHOU, China and LONDON, May 27, 2025 GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a comm

PR NewswireGUANGZHOU, China and LONDON, May 27, 2025 GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a comm

The agreement will see Hikma take over all channels for Combogesic Rapid in the US — apart from the license granted to Alexso for certain specific market categories — allowing both forms of AFT’s patented medicines to be marketed across the entire ...

**media[618037]**

Summary Hikma Pharmaceuticals PLC (HKMPY), a leading multinational pharmaceutical company, announced on April 17, 2025, that it has acquired the FDA-approved Ab

PR NewswireLONDON, April 17, 2025 LONDON, April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and

**media[571897,571898]**

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada

Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in N

Release Date: February 26, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hikma Pharma

Feb 26, 2025 / 09:00AM GMTRiad Mishlawi - Hikma Pharmaceuticals PLC - Chief Executive Officer, Executive Director Thank you for joining our 2024 full-year resul

U.K. stocks lower at close of trade; Investing.com United Kingdom 100 down 1.23%

U.K. stocks higher at close of trade; Investing.com United Kingdom 100 up 1.38%

The Cancer Cachexia Market Size sector reached a market value of USD 2.02 Billion in 2019. Future projections show a bright outlook, with a Compound Annual Growth Rate (CAGR) of 5% from 2019 to 2032…

Sickle Cell Disease Market Size Was Valued at USD 2.40 Billion in 2023, and is Projected to Reach USD 12.38 Billion by 2032, Growing at a CAGR of 20.00%...

The need for antiemetic drugs, which help prevent or relieve nausea and vomiting, is growing for several reasons. A key factor is the rising incidence of...

Huntingtons disease treatment industry is projected to witness a CAGR of 20.8% during the period 2024-2032. This growth can be attributed to the limited...